
Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

